Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Aug 02, 2022 12:56pm
207 Views
Post# 34866088

RE:RE:RE:RE:RE:RE:RE:Beam Therapeutics Phase 1 CAR-T study placed on hold by FDA

RE:RE:RE:RE:RE:RE:RE:Beam Therapeutics Phase 1 CAR-T study placed on hold by FDA

" swing trader"?

perhaps you are over reacting.
I did say I have owned Onc on & off since 1998.
The bulk of my holdings have been since when Matt took over for retired Brad T. 

lost track of dates, but I believe 2017. 

when I " bought back in"
That was not long before the A.N. Announcement.
I have bought more, last few months, notably when it was bellow $1 on the NAS.
And yes, I did sell SOME  into the spikes. 

point being a very small % of my total holdings.
Why do I continue to hold Onc & not sell all? Even Dec 2019, when there was a reasonable spike?
I truly believe in the science.
I have read 90%++ of SEDAR documents, log into every on- line meeting available.study the published abstracts.etc etc 
I truly believe that between Co- development trails & support that Onc has with Roche, Pfizer, Incyte, Merck etc, that there should be something that comes out of this.
Why would I sell some on spikes? & buy back in in dips ?
To lower my break even costs. & balance my overall risk.
One way or the other, I'm in this until a deal is done.
A complete buyout, would make the decision for me.
A partnership ? I'd sell some....depending on SP & operational details.
I can not be any more clear than that.
Miles from supisious unless the reader is paranoid.
Now, that I have that off my chest. Back to Onc.....

The Q2 results, typically last 6/7 years has been first week of Aug.
the one time it was delayed ( as in this month being second time), when they announced the start of Bracelet trial with Pfizer.
IMHO ( suspicious), They will need to address the final enrolment of Bracelet, either during or before Q2.
My prediction FWIW, next Tuesday.
the only thing suspicious is why they have not discussed final enrolment?


 


 

<< Previous
Bullboard Posts
Next >>